Posts
- Renal drug handling and drug-drug interactions in ADMET
- Antibody drug conjugates (ADCs) – the role of in vitro models in safety assessment
- The inside story of the development of Newcells’ MPS flow model: Scientific chat with Dr Colin Brown
- Newcells Biotech collaborates with consortium in Eurostars funded project to advance novel therapy for Alpha-1 Antitrypsin (AAT) Deficiency
- The latest FMT Assay: An invaluable tool for modelling fibrotic disease
- New Product Launched – aProximate™ 96-well Assay-Ready Plates
- NB staff supports Motor Neurone Disease Charity
- Newcells team support charity with festive jumpers
- NB completes a licensing agreement with ID Pharma Co. Ltd for induced pluripotent stem cell technologies
- NB to develop a new skin metabolism model using iPSC derived skin cells
- Development of iPSC-derived conducting airways & application to toxicity testing
- Newcells Biotech joins StemBANCC consortium
- Latest innovation in retina models brings a fully characterised Retina Pigment Epithelium (RPE)
- hiPSCs derived cells in disease modelling
- Current cell-based screens are poor models of human biology
- NB to develop 3D retinal organoids using hiPSC derived skin cells
- British Toxicological Society Annual Congress 2018 – Hilton Gateshead (16th-18th April)
- Dr Chichagova awarded best In Vitro Toxicology Society poster
- FMS Post-Doc Symposium 2018 – Newcastle University (15th June 2018)
- 17th Annual World Preclinical Congress – Boston, MA (18th-21st June)
- Review article – Cellular regeneration strategies for macular degeneration: past, present & future
- How the NHS Changed Our World: Tyneside’s Genetic Pioneers on BBC 1 (North East & Cumbria)
- NB secures £2M investment from NVM Private Equity & Northstar Ventures to accelerate hiPSC growth
- 22nd North American ISSX Meeting – Montréal, Canada (15th-19th July)
- Newcells Biotech strengthens executive and US team with key appointments
- Press Release: Newcells Biotech raises additional funding from investors
- How is AI Impacting drug discovery?
- Transforming Drug Development with 3D Retina Models
- Ask an expert: What are the latest trends in in vitro models?
- Scientific discussion with our CSO: what is next for in vitro models?
- Newcells Biotech launches Lung Ciliary Beat Frequency assay to enhance safety and efficacy profiling in preclinical drug development
- The Intensity of Innovation: Insights from the Japanese Society of Toxicology Conference
- Latest advances in In Vitro models
- Press Release: Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes
- Press Release: Newcells Biotech appoints Emile Shaffu as Director of Sales
- Newsletter June 2024
- Leading drug transport & drug toxicity expert, Dr Colin Brown joins NB
- Press Release : Newcells Biotech strengthens executive and US team with key appointments
- Biotech firm raises £2.3m for lab models that help avoid animal testing
- Dr Emanuela Costigliola joins Newcells Biotech’s executive team as a Chief Marketing Officer
- Overcoming optimisation hurdles of high-throughput FMT assay
- An insight into R&D at Newcells Biotech with Dr Fiona Leslie, PhD, Lung platform scientist
- Mr Terry Pizzie joins Newcells Biotech Board as non-executive director
- Imaging propels our kidney assays to the next level
- Latest Advances in CAR-T Therapy with novel HLA-typed in vitro cell tools
- MPS summit highlights
- 3rd ILD Summit Highlights
- ARVO Highlights
- Lung epithelium in vitro modelling of SARS-CoV2 infections to aid Covid-19 treatments
- Development of functioning in vitro lung assay for modelling Covid-19 infection
- Diagnosing unresolved Stargardt disease using retina-specific splicing isoforms obtained from retinal organoids
- Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
- Improved in vitro renal tubular drug transport modelling to meet regulatory & development cost challenges
- Covid-19 action plan – 2021 update
- Developing a 3D in vitro proximal tubule model for chronic toxicity studies
- Newcells Biotech secures over £5m for 3D tissue models
- Our commitment to the 3Rs
- Successful EU initiative adds a new 3D lung airway model to NB’s portfolio for drug safety testing
- NB collaborates with Takeda Pharmaceuticals on renal drug safety evaluation study
- Global scientific expertise built into every NB product & service
- Newcells scales up its operations in The Biosphere
- Thought Leadership Workshop hosted by NB: Emerging in vitro technologies for gene therapy applications
- In vitro models for chronic kidney disease (CKD)
- iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery
- Dr Kathryn Garner, Head of Kidney Development at NB
- How to reduce drug attrition during drug development?
- Why is an in vitro model of the glomerulus desperately needed?
- New Product Launched – aProximate™ Assay-Ready Plates for transporter studies
- How a glomerulus in vitro model can accelerate drug development
- Retinal Organoids for Drug Discovery
- Gene therapy vectors: Preclinical testing with retinal organoids
- Organ-on-a-chip: the next generation tool for drug development?
- Dr Frank Armstrong appointed as Non-executive Director
- iPSC-derived retinal organoids
- ESTIV 2018 International Congress
- Newcells head to Boston
- Looking forward: A year in review
- WHY WE DO IT
- HOW WE DO IT
- WHAT WE DO
- WHO WE ARE
- NB win Phase I of CRACK IT Challenge 29: ImmuLiver – securing £99,711 funding
- Newcells Biotech technology: the fight against antibacterial resistance
- iPSC derived retinal organoids: A promising tool for modelling retinitis pigmentosa
- NB completes a licensing agreement with iPS Academia Japan, Inc. for induced pluripotent stem cell technologies
- NB RPE model to improve drug retinal toxicity assessment
- Vision for the future of childhood retinal dystrophies
- Newcells Biotech acquires IP for retinal organoids
- NB hiPSC lung models; Valuable tools in understanding health impacts of air pollution
- NB win Phase II of CRACK IT Challenge 29: ImmuLiver
- Pulmonary toxicity – a challenge for drug development
- Covid-19 action plan – A message to our customers, collaboration partners & colleagues
- NB testing an in vitro model of the human lung epithelium for application in the fight against SARS-CoV-2
- The Human Cell Atlas – an aid to understanding COVID-19 & a valuable tool in the development of hiPSC models
- Biologics & the kidney – importance of transport & safety assessment
- An overview of vaccine development & sub-types
Pages
- The most advanced, freshly isolated in vitro kidney proximal tubule cell (PTC) model for nephrotoxicity assays
- Sitemap
- Contact – Service Enquiries
- Contact – Product Enquiries
- Accelerate Your Drug Discovery
- Lung Ciliary Beat Frequency Analysis
- State-of-the-Art Imaging Suite
- TERMS AND CONDITIONS FOR SALE OF PRODUCT & SERVICES
- Pipeline
- Fibroblast-to-Myofibroblast Transition Assay
- Small Airway Epithelial Cell Model
- Privacy Policy
- Contact
- Terms of Use
- Updates
- About
- Resources
- In Vitro Models
- Homepage
- FAQs
- Applications
Resources
- Retinal Organoids eBook
- Application of organoid technology for retinal disease modelling & drug discovery
- Lung Model Aids SARS-CoV-2 Research
- Development of a physiologically relevant lung model for understanding SARS-CoV-2 infection
- In vitro platforms for de-risking nephrotoxicity during drug development
- aProximate™ Assay-Ready Plates (Human, 24-well) User Guide
- Renal Proximal Tubule Cells Model eBook
- Improved in vitro renal tubular drug transport modelling to meet challenges
- The aProximate™ in vitro renal proximal tubule cell model as a platform to investigate the renal uptake and nephrotoxic liability of biologics
- An inter-species comparison of the triclopyr in vitro and in vivo toxicokinetic properties, for risk assessment purpose
- Development of predictive in vitro cross-species proximal tubule models for nephrotoxicity studies
- Development of a predictive in vitro human proximal tubule platform for de-risking nephrotoxicity
- Human primary proximal tubule cell monolayers as a novel predictive model of nephrotoxicity
- Characterization of cisplatin toxicity in aProximate™ human proximal tubule cell monolayers
- P52 – Determination of aminoglycoside toxicity in human renal proximal tubule monolayers using clinical relevant biomarkers of nephrotoxicity
- Complementary in vitro tools to investigate renal drug transport
- Primary human proximal tubule cell monolayers as a predictive model of renal phosphate homeostasis in heath & disease
- Improved phenotype of human proximal tubule epithelial cells in a 3D microfluidic model
- Developing High Content Imaging Assays for Chronic Kidney Disease
- Human induced pluripotent stem cell (hiPSC)-derived retinal model containing microglial cells
- Retinal Organoids as an Emerging Tool for Drug Discovery
- The Kidney as a Therapeutic Target: Targeting Therapeutics to the Proximal Tubule
- NIH/NEI 3D-ROC Sponsor Webinar
- A human iPSC-derived model of SARS-CoV-2 infection & pathogenesis in the lung
- Reducing compound attrition by predicting renal tubular toxicity with in vitro PTEC models
- Predictive in vitro primary proximal tubule models for understanding nephrotoxicity in drug development programs
- JSAAE Poster Presentation
- Tropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids
- Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling
- Human-induced pluripotent stem cells generate light responsive retinal organoids with variable and nutrient-dependent efficiency
- Freshly isolated primary human proximal tubule cells as an in vitro model for the detection of renal tubular toxicity
- Room temperature shipment does not affect the biological activity of pluripotent stem cell derived retinal organoids
- Derivation of a system-independent Ki for p-glycoprotein mediated digoxin transport from system-dependent IC50 data
- In vitro models for accurate prediction of renal tubular xenobiotic transport in vivo
- Enhancing immune function of hiPSC-derived retinal organoids by incorporating microglial cells
- Human iPSC differentiation to retinal organoids in response to IGF1 and BMP4 activation is line- & method-dependent
- Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics
- Using statistical models to identify key variables critical for generation of retinal organoids from iPSC
- Differentiation of retinal organoids from human pluripotent stem cells
- aProximate™ as a novel, predictive model of aminoglycoside-induced nephrotoxicity
- Development of a novel predictive in vitro non human primate proximal tubule model for drug transporter & nephrotoxicity studies
- c-Rel orchestrates energy-dependent epithelial & macrophage reprogramming in fibrosis
- The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane
- The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression & function in the proximal tubule
- The importance of incorporating OCT2 plasma membrane expression and membrane potential in IVIVE of metformin renal secretory clearance
- Review of pharmacokinetics & metabolism of triclopyr herbicide in mammals: Impact on safety assessments
-
In vitro selection of the most relevant species to predict human
- The chlorophenoxy herbicide MCPA: A mechanistic basis for the observed differences in toxicological profile in humans & rats vs dogs.
- Incorporating microglia-like cells in human induced pluripotent stem cell-derived retinal organoids
- aProximate™ Assay-Ready Plates (Human, 96-well) User Guide
- MPS World Summit 2022: in vitro model of podocyte damage
- Development of highly-differentiated human primary proximal tubule MPS model
- A solution for shipping primary human proximal tubule cell monolayers between laboratories
- The aProximate™ in vitro renal proximal tubule cell model as a platform to investigate the renal uptake & nephrotoxic liability of Antisense Oligonucleotide drug molecules
- Developing a Comprehensive Biomarker Package for Detecting Drug-Induced Injury in Podocytes
- In vitro evaluation of ocular toxicity and phenotypic rescue
- Primary Kidney Cells for Modelling Chronic Kidney Disease in vitro
- Retinal organoids as a tool for in vitro pre-clinical testing
- Quantitative Fibroblast-to-Myofibroblast Transition (FMT) studies
- Comparison of multiple batches of human iPSC-derived retinal organoids produced at large scale
- An in-vitro high-content imaging assay for the study of fibroblast activation and matrix deposition
- The aProximate™ in vitro renal proximal tubule cell model as a platform to investigate the renal uptake and nephrotoxic liability of Antisense Oligonucleotide drug molecules
- Development of highly-differentiated human primary proximal tubule MPS model (aProximate MPS™ Flow)
- Meet Dr Valeria Chichagova – Our Associate Director of iPSC technology and Head of Retina
- Retinal Model Capabilities
- A Live Cell High Content Imaging Assay for Monitoring Large Molecules Uptake into aProximateTM Proximal Tubule Epithelial Cells via Megalin and Cubulin
- Latest trends in Retinal Organoids: Scientific chat with Dr Valeria Chichagova
- The inside story of lung in vitro models with Dr Megan Webster
- Q&A with Dr Carolina Gandara, Head of retina assay development
- Meet Dr Megan Webster – Head Of Lung Development (2020-2024)
- A Sensitive Nephrotoxicity Assay of in vitro Podocyte Effacement
- Significance of OAT2 and OCT2 in creatinine clearance: Mechanistic evaluation using freshly-prepared human primary renal proximal tubule cells
- Overcoming technical difficulties of in vitro assay – development
- Development of a Highly Differentiated Human Primary Proximal Tubule MPS Model (aProximate MPS Flow)
- The inside story of the development of Newcells’ MPS flow model: Scientific chat with Dr Colin Brown
- A predictive in vitro primary proximal tubule platform for derisking of antibiotic-induced kidney injury
- Dr Mike Nicholds – About the company
- An in vitro Human Primary Thick Ascending Limb Model For The Assessment of Compound Nephrotoxicity
- A Primary Human in vitro Focal Segmental Glomerulosclerosis (FSGS) model for drug development applications
- Lung models eBook
- A high-throughput, in vitro assessment of antibiotic induced podocyte injury
- An in vitro model that predicts Antibiotic Renal Toxicity
- Modelling Epithelial Barrier Function and Mucociliary Clearance Using Small Airway Epithelium Cells
- Developing predictive in vitro Glomerulus , Proximal Tubule and Loop of Henle renal cell model platforms to investigate the renal uptake and nephrotoxic liability of large molecules
- Development of photoreceptor outer segments in human iPSC derived retinal organoids produced at large scale
- Evaluation of glomerular ADC toxicity in podocytes
- The aProximateTM model for renal drug safety/efficacy and transporter studies
- Comparison of the Impact of VRP-034 and Polymyxin B upon markers of Kidney Injury in Human Proximal Tubule Monolayers In Vitro
- Newcells Biotech strengthens executive and US team with key appointments
- High content imaging (HCI) assays enable the study of the fibrotic processes: fibroblast – to – myofibroblast transition (FMT) and epithelial – to – mesenchymal transition (EMT)
- Moving compounds to IND using predictive retina models
- High throughput, high sensitivity (HTHS) lung fibroblast-to-myofibroblasts transition (FMT) assay for anti-fibrotic drug screening
- Dr Mike Nicholds – How Newcells works with Clients
- Dr Mike Nicholds – Newcells Offerings
- Meet Dr Kathryn Garner – Head of Kidney Development
- Newcells Biotech – Kidney Model Capabilities
- Utilization of high – content imaging for the study of lung fibrosis
- Small airway epithelial cell (SAEC) model
- The aProximateᵀᴹ Proximal tubule cells (PTC) model
- iPSC-derived Retinal Organoids (RO)
- iPSC-derived Retinal Pigment Epithelium (RPE)
- Ciliary beat frequency analysis assay for lung small airway epithelium cells (SAEC)
- Gene therapy viral vector assessment on retinal organoids
- Gene therapy viral vector assessment on RPE cells
- Meet the scientists: Anusha Gupta, the scientist behind the development of the CBF assay
- Meet the scientists: Dr Fiona Leslie, the scientist behind the development of the advanced FMT assay
- Creating a Powerful NAM respiratory Toxicology Strategy for Clinical Predictivity and IND success
- Lung Model Capabilities
Events
- Webinar: Moving compounds to IND using predictive retina models
- 3D Cell culture & Organ Modelling 2024
- 6th CKD Summit
- ARVO 2024
- 22nd International Congress ESTIV
- ECM Pharmacology Congress 2024
- MPS World Summit 2024
- The 51st Annual Meeting of the Japanese Society of Toxicology
- BVS – Biotech Community Celebration at Tech Square
- SOT 63rd Annual Meeting
- 8th Annual IPF Summit
- 5th Gene Therapy for Opthalmic Disorders Summit
- Newcells Seminar Tour
- ERS Congress 2024
- Discovery on Target
- 20th Annual Meeting of the Oligonucleotide Therapeutics Society
- Online fireside chat: Creating a Powerful NAM respiratory Toxicology Strategy for Clinical Predictivity and IND success
- ASN Kidney Week 2024
- 3rd Annual Gene Therapy for Ophthalmic Disorders
- SOT 62nd Annual Meeting
- 5th Chronic Kidney Disease Drug Development Summit
- 1st Annual Translational Research Conference
- Organ Modelling UK
- ARVO 2023
- International Society for Cell & Gene Therapy
- World Organoid Research Day
- 19th Annual Meeting of the Oligonucleotide Therapeutics Society
- 13ᵀᴴ International ISSX and MDO Meeting
- MPS World Summit 2023
- 3D Cell Culture Conference
- ELRIG: Drug Discovery 2023
- 25th American ISSX Meeting
- Applied Pharmaceutical Toxicology (APT) 2023
- 3rd ILD Summit
- JSOT 2023
- Bioinfect Liverpool 2024
